Latest News

Biogen, Eisai complete submission of controversial Alzheimer’s drug. The ball is in FDA’s court now.


Dementia or brain damage and injury as a mental health and neurology medical symbol with a thinking human organ made of crumpled paper torn in pieces as a creative concept for alzheimer disease.

The FDA has 60 days to decide whether or not to accept the application. An analyst wrote that the agency accepting it with a priority or standard review may signal whether the agency is seriously considering approval or has continued reservations about the amyloid beta-targeting drug’s clinical benefit.

Source link

Related posts

Policy changes help reduce opioid prescriptions at Kellogg Eye Center cornea clinic

Newsemia

Non-Oncology Drugs Surprisingly Capable Of Killing Cancer Cells

Newsemia

UN treaty cracks down on heated tobacco products

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World